TOLREMO therapeutics
TOLREMO therapeutics is a biopharmaceutical company that develops small molecule inhibitors targeting non-genetic cancer drug resistance pathways, specifically blocking transcriptional escape mechanisms that enable cancer cells to survive targeted therapies. The company's mission is to tackle non-oncogene addiction in cancer by blocking transcriptional escape pathways that operate parallel to the primary oncogene…
Funding snapshot
About
TOLREMO therapeutics is a biopharmaceutical company that develops small molecule inhibitors targeting non-genetic cancer drug resistance pathways, specifically blocking transcriptional escape mechanisms that enable cancer cells to survive targeted therapies. The company's mission is to tackle non-oncogene addiction in cancer by blocking transcriptional escape pathways that operate parallel to the primary oncogene signaling axis. Leveraging a proprietary phenotypic screening platform, TOLREMO has uncovered a novel role for CBP/p300 as an epigenetic master regulator of transcriptional resistance. The company's lead clinical compound, TT125-802, is an orally available small molecule inhibitor of the bromodomain of CBP/p300 with a differentiated, best-in-class safety profile and activity as a single agent in solid tumors. TT125-802 blocks the transcription of genes involved in primary and acquired resistance to targeted treatment, representing a novel therapeutic approach to addressing a major challenge in cancer treatment. The clinical development plan focuses on prevention of resistance by combining TT125-802 with a range of targeted therapies, following rapid dose escalation as monotherapy, while also exploring the compound's monotherapy activity in non-small cell lung cancer. TOLREMO's strategy of targeting non-oncogene addiction represents a differentiated approach with significant therapeutic potential both as monotherapy and in combination with targeted therapies in solid tumors and hematological malignancies. The company's team brings expertise in medicinal chemistry, bioinformatics, and therapeutic development. Founded in 2017 and headquartered in Zurich, Switzerland, TOLREMO therapeutics has raised $55.8M in Series A funding from investors including BioMedPartners, Altos Ventures Management, Redalpine, Zurcher Kantonalbank, MK Venture Capital, HEMEX, Wille Finance, EIT Health, BaseLaunch, and InQbator.
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Cheminformatics,
Oncology > Drugs > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Team background
College Wise > University of California (Berkeley)
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.
Raising like TOLREMO therapeutics?
Analyze your pitch deck before your next raise.
Analyze My Deck →